HNF-4γ inhibitors belong to a specialized category of chemical compounds that are recognized for their unique capacity to modulate the activity of Hepatocyte Nuclear Factor 4 Gamma (HNF-4γ). This transcription factor plays a significant role in regulating gene expression within the context of cellular development, differentiation, and metabolic homeostasis. The inhibitors designed for HNF-4γ operate by interfering with its natural function, often by competitively binding to its active site or altering its conformation. By impeding HNF-4γ's binding to DNA, these inhibitors can essentially influence downstream gene expression patterns, leading to a cascade of molecular events that can have far-reaching implications. Structurally diverse, HNF-4γ inhibitors are meticulously crafted to target the transcription factor with high specificity. These compounds typically interact with key amino acid residues within the binding pocket of HNF-4γ, which prevents its successful interaction with DNA sequences.
Inhibitors may function through various mechanisms, such as steric hindrance, electrostatic interactions, or allosteric modulation. Researchers often employ advanced computational modeling and structure-based drug design techniques to engineer compounds with optimized binding affinities and selectivities. Understanding the intricate molecular interactions between these inhibitors and HNF-4γ is pivotal in advancing our comprehension of gene regulation mechanisms and cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A66 | 1166227-08-2 | sc-364394 sc-364394A | 5 mg 50 mg | $255.00 $1455.00 | ||
A-66 is an experimental HNF-4γ inhibitor with potential applications in cancer therapy. It works by disrupting the interaction between HNF-4γ and its coactivators, affecting tumor growth pathways. | ||||||
BI 6015 | 93987-29-2 | sc-503543 | 10 mg | $380.00 | ||
BI6015 is a compound that inhibits HNF-4γ by binding to its ligand-binding domain. It's being investigated for its potential in liver diseases and metabolic disorders. | ||||||
PK 11195 | 85532-75-8 | sc-203199 sc-203199A | 10 mg 50 mg | $88.00 $321.00 | ||
While originally developed as a ligand for peripheral benzodiazepine receptors, PK11195 has been found to have HNF-4γ inhibitory effects. It might have implications for liver diseases. | ||||||